XML 24 R13.htm IDEA: XBRL DOCUMENT
v3.10.0.1

Debt | 9 Months Ended
--- | ---
Sep. 29, 2018
Debt Disclosure [Abstract] |
Debt | Note 5 – Debt Bank Credit Line s O n April 18, 2017, we entered into a new $750 million revolving credit agreement (the “Credit Agreement”). This facility, which matures in April 2022, replaced our $500 million revolving credit facility, which was scheduled to mature in September 2019. The interest rate is based on the USD LIBOR plus a spread based on our leverage ratio at the end of each financial reporting quarter. On June 29, 2018, we amended the Cr edit A greement to, among other things, (i) permit the consummation of the spin-o ff of our Animal Health business (the “Spin-off”) (S ee Note 9), (ii) provide for swing-line commitments in the amount of $75 million, and (iii) provide for the designation of s ubsidiary borrowers under the facility. The Credit Agreement provides, among other things, that we are required to maintain maximum leverage ratios, and contains customary representations, warranties and affirmative covenants. The Credit Agreement also c ontains customary negative covenants, subject to negotiated exceptions on liens, indebtedness, significant corporate changes (including mergers), dispositions and certain restrictive agreements. As of September 29, 2018 and December 30, 2017, the bor rowings under this revolving credit facility were $350.0 million and $320.0 million, respectively. As of September 29, 2018 and December 30, 2017, there were $11.2 m illion and $11.3 million of letters of credit, respectively, provided to third parties under the credit facility. As of September 29, 2018 and December 30, 2017, we had various other short-term bank credit lines available, of which $394.9 m ill ion and $421.7 million, respectively, were outstanding. At September 29, 2018 and December 30, 2017, borrowings under all of our credit lines had a weighted average interest rate of 3.06% and 2.27%, respectively. Private Placement Facilities On September 15, 2017, we increased our available private placement facilities with three insurance companies to a total facility amount of $1 billion, and extended the expirati on date to September 15, 2020. These facilities are available on an uncommitted basis at fixed rate economic terms to be agreed upon at the time of issuance, from time to time through September 15, 2020. The facilities allow us to issue senior promissory notes to the lenders at a fixed rate based on an agreed upon spread over applicable treasury notes at the time of issuance. The term of each possible issuance will be selected by us and can range from five to 15 years (with an average life no longer than 12 years). The proceeds of any issuances under the facilities will be used for general corporate purposes, including working capital and capital expenditures, to refinance existing indebtedness and/or to fund potential acquisitions. On June 29, 2018, we amended and restated the above p rivate placement facilities to, among other things, (i) permit the consummation of the Spin-off and (ii) provide for the issuance of notes in Euros, British Pounds and Australian Dollars, in addition to U.S. Dollars. The agreements provide, among other th ings, that we maintain certain maximum leverage ratios, and contain restrictions relating to subsidiary indebtedness, liens, affiliate transactions, disposal of assets and certain changes in ownership. These facilities contain make-whole provisions in the event that we pay off the facilities prior to the applicable due dates. The components of our private placement facility borrowings as of September 29, 2018 are presented in the following table (in thousands):
|  | Amount of |  |  |  |  |
|  | Borrowing |  | Borrowing |  |
Date of Borrowing |  | Outstanding |  | Rate |  | Due Date
September 2, 2010 |  | $ | 100,000 |  | 3.79 | % |  | September 2, 2020
January 20, 2012 |  |  | 50,000 |  | 3.45 |  |  | January 20, 2024
January 20, 2012 (1) |  |  | 28,571 |  | 3.09 |  |  | January 20, 2022
December 24, 2012 |  |  | 50,000 |  | 3.00 |  |  | December 24, 2024
June 2, 2014 |  |  | 100,000 |  | 3.19 |  |  | June 2, 2021
June 16, 2017 |  |  | 100,000 |  | 3.42 |  |  | June 16, 2027
September 15, 2017 |  |  | 100,000 |  | 3.52 |  |  | September 15, 2029
January 2, 2018 |  |  | 100,000 |  | 3.32 |  |  | January 2, 2028
Less: Deferred debt issuance costs |  |  | (439) |  |  |  |  |
|  | $ | 628,132 |  |  |  |  |
(1) Annual repayments of approximately $7.1 million for this borrowing commenced on January 20, 2016.
Committed Loan Associated with Animal Health Spin-off On May 21, 2018, we obtained a $400 million committed loan which matures on the earlier of (i) March 31, 2019 and (i i) the consummation of the Spin-off. The proceeds of this loan were used, among other things, to fund our purchase of all of the equity interests in Butler Animal Health Holding Company, LLC (“BAHHC”) directly or indirectly owned by Darby Group Companies, Inc. (“Darby”) and certain other sellers pursuant to the terms of that certain Amendment to Put Rights Agreements, dated as of April 20, 2018, by and among us, Darby, BAHHC and the individual sellers party thereto for an aggregate purchase price of $365 million. As of September 29, 2018, the balance outstanding on this loa n was $400 million and is included within the “Bank credit lines” caption within our consolidated balance sheet. At September 29, 2018, the interest rate on this loan was 3.125%. U.S. Trade Accounts Receivab le Securitization We have a facility agreement with a bank, as agent, based on the securitization of our U.S. trade accounts receivable that is structured as an asset-backed securitization program with pricing committed for up to three years. On June 1, 2016, we extended the expiration date of this facility agreement to April 29, 2019 and increased the purchase limit under the facility from $300 million to $350 million. On July 6, 2017, we extended the expiration date of this facility agreement to April 29, 2020. The borrowings outstanding under this securitization facility were $350 million and $350 million as of September 29, 2018 and December 30, 2017, respectively. At September 29, 2018, the interest rate on borrowings under this facility was based on the asset-backed commercial paper rate of 2.31% plus 0.75%, for a combined rate of 3.06%. At December 30, 2017, the interest rate on borrowings under this facility was based on the asset-b acked commercial paper rate of 1.53% plus 0.75%, for a combined rate of 2.28%. We are required to pay a commitment fee of 30 basis points on the daily balance of the unused portion of the facility if our usage is greater than or equal to 50% of the facility limit or a commitment fee of 35 basis points on the daily balance of the unused portion of the facility if our usage is less than 50% of the facility limit. Borrowings under this facility are presented as a component of Long-term debt within our consolidated balance sheet. Long-term debt Long-term debt consisted of the following:
|  |  | September 29, |  | December 30,
|  |  | 2018 |  | 2017
Private placement facilities |  | $ | 628,132 |  | $ | 535,295
U.S. trade accounts receivable securitization |  |  | 350,000 |  |  | 350,000
Various collateralized and uncollateralized loans payable with interest |  |  |  |  |  |
| in varying installments through 2022 at interest rates |  |  |  |  |  |
| ranging from 2.61% to 4.73% at September 29, 2018 and |  |  |  |  |
| ranging from 2.56% to 12.90% at December 30, 2017 |  | 29,719 |  |  | 34,027
Capital lease obligations payable through 2029 with interest rates |  |  |  |  |  |
| ranging from 0.07% to 19.79% at September 29, 2018 and |  |  |  |  |
| ranging from 0.84% to 19.79% at December 30, 2017 |  | 4,946 |  |  | 5,093
Total |  |  | 1,012,797 |  |  | 924,415
Less current maturities |  |  | (12,482) |  |  | (16,659)
| Total long-term debt |  | $ | 1,000,315 |  | $ | 907,756

X
- References No definition available. + Details
Name: | us-gaap_DebtDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -URI http://asc.fasb.org/topic&trid=2208564 + Details
Name: | us-gaap_DebtDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration